Erasca, Inc. cotiza a 14.72 USD y tiene una capitalización bursátil de $5.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-40…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.60 | $-0.10 |
| Estimado | $-0.13 | $-0.11 | $-0.23 | $-0.11 |
| Sorpresa | — | — | -160.9% | +9.1% |
| Métrica | ERAS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -38.3% | -40.4% | +2.1% |
| ROA | -31.4% | -32.0% | +0.6% |
| Current Ratio | 10.04 | 2.84 | +7.20 |
| Debt / Equity | — | 0.28 | — |